Investors Purchase Large Volume of Call Options on Ventyx Biosciences (NASDAQ:VTYX)

Ventyx Biosciences, Inc. (NASDAQ:VTYX) was the target of unusually large options trading on Tuesday. Stock traders bought 2,207 call options on the stock. This represents an increase of approximately 299% compared to the typical volume of 553 call options.

Ventyx Biosciences Price Performance

NASDAQ VTYX traded down $0.07 on Tuesday, hitting $1.09. 846,321 shares of the company’s stock were exchanged, compared to its average volume of 1,243,505. The firm has a market cap of $77.18 million, a price-to-earnings ratio of -0.46 and a beta of 0.58. The firm’s 50-day moving average price is $1.62 and its two-hundred day moving average price is $2.04. Ventyx Biosciences has a fifty-two week low of $1.07 and a fifty-two week high of $5.66.

Ventyx Biosciences (NASDAQ:VTYX) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.13. On average, research analysts predict that Ventyx Biosciences will post -2.09 earnings per share for the current fiscal year.

Institutional Trading of Ventyx Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE boosted its stake in shares of Ventyx Biosciences by 376.4% during the 4th quarter. Bank of America Corp DE now owns 4,273,442 shares of the company’s stock worth $9,359,000 after acquiring an additional 3,376,446 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Ventyx Biosciences during the fourth quarter worth about $3,903,000. Millennium Management LLC lifted its holdings in shares of Ventyx Biosciences by 369.7% in the fourth quarter. Millennium Management LLC now owns 1,281,629 shares of the company’s stock valued at $2,807,000 after purchasing an additional 1,008,760 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Ventyx Biosciences by 88.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 871,527 shares of the company’s stock valued at $1,909,000 after purchasing an additional 409,357 shares during the last quarter. Finally, Two Sigma Advisers LP increased its stake in shares of Ventyx Biosciences by 72.1% during the 4th quarter. Two Sigma Advisers LP now owns 800,800 shares of the company’s stock worth $1,754,000 after purchasing an additional 335,400 shares in the last quarter. Institutional investors and hedge funds own 97.88% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “neutral” rating on shares of Ventyx Biosciences in a research report on Tuesday, January 14th.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.